Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RESEARCH TOOLSreports
Ultragenyx Pharmaceutical (RARE) Stock Price & Analysis
686 Followers
RARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$31.52 - $54.56
Previous Close$42.55
Volume606.78K
Average Volume (3M)880.70K
Market Cap
$3.85B
Enterprise Value$3.44B
Total Cash (Recent Filing)$412.08M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 01, 2024EPS Estimate
-$1.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.03
Shares Outstanding83,133,341
10 Day Avg. Volume1,293,322
30 Day Avg. Volume880,704
Standard Deviation0.14
R-Squared0.05
Alpha-0.00300
Financial Highlights & Ratios
Price to Book (P/B)-47.58
Price to Sales (P/S)25.84
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.04
Enterprise Value/Gross Profit8.85
Enterprise Value/Ebitda-11.92
Forecast
1Y Price Target
$89.67Price Target Upside110.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Ultragenyx Pharmaceutical News
PremiumCompany Announcements
Ultragenyx Shareholders Approve Directors and Incentive Plans
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignThe pivotal Ph3 trial will be a global, randomized, double-blind, sham-controlled trial and will include a 48-week primary efficacy analysis period enrolling approximately 120 pts with deletion type Angelman syndrome pts.
Drug EfficacyThe 14-month data continue to demonstrate a meaningful reduction in fracture rate and we note that 12-month measures also point to a continued improvement of the effects on both BMD and Z-score as patients remain on treatment.
Regulatory ApprovalFDA has agreed to Bayley-4 Cognition as the primary endpoint for the Ph3 pivotal study of GTX-102 in Angelman Syndrome.
Bears Say
Commercial OpportunityBears have pointed to some uncertainty on the commercial opportunity.
Revenue Performance1Q24 revenues of $109M vs Street of $116M.
Safety Concerns76% of DTX401 treated patients experienced liver enzyme elevations.
---
Ownership Overview
9.06% Insiders
31.98% Mutual Funds
14.46% Other Institutional Investors
44.50% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $31.52 and its highest was $54.56 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Currently, no data Available
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on May 02, 2024. The company reported -$2.03 earnings per share for the quarter, missing the consensus estimate of -$1.747 by -$0.283.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -$1.66.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 90,569,240 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$2.03 in its last earnings report, missing expectations of -$1.747. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Sands Capital Management LLC. It holds Ultragenyx Pharmaceutical’s shares valued at 180M.
---
Ultragenyx Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.67 (110.74% Upside)
$89.67 (110.74% Upside)
Blogger Sentiment
Neutral
RARE Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 109.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $110.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.34%
12-Months-Change
Fundamentals
Return on Equity
-340.05%
Trailing 12-Months
Asset Growth
-5.52%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
---
RARE Company Deck
---
RARE Earnings Call
Q1 2024
0:00 / 0:00
---
RARE Stock 12 Month Forecast
Average Price Target
$89.67
▲(110.74% Upside)
Technical Analysis
Best Analysts Covering RARE
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+12.37%
assigned a buy rating 4 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +12.37% per trade.
---